Published 2011 | Version v1
Journal article

17a-Ethynyl-5a-androstane-3a, 17 β-diol Treatment of MNU-Induced Mammary Cancer in Rats

  • 1. Harbor BioSciences, Inc., 9171 Towne Centre Drive, Suite 180, San Diego, CA 92122 (Ukraine)
  • 2. Center of Excellence in Cancer Research, Department of Biomedical Sciences, Texas Tech University Health Sciences Center, 4800 Alberta Ave, El Paso, TX 79905 (Ukraine)

Description

N-methyl-N-nitrosourea (MNU) induces estrogen-dependent mammary tumors in female Lewis rats. We explored the antineoplastic activity of a synthetic androstane derivative, 17 a-ethynyl-5a-androstane-3a, 17β-diol (HE3235), as a single agent or in combination with docetaxel compared to tamoxifen, anastrazole, and docetaxel mono therapies against MNU-induced mammary tumors in female Lewis rats. Treatment with HE3235 alone rapidly reduced tumor burden, similar in effect to tamoxifen and anastrozole. The combination of HE3235 with docetaxel was more effective than any single agent, although without apparent toxicity. Only HE3235 or HE3235 plus docetaxel continued to suppress tumor growth after cessation of treatment. HE3235 treatment increased immunohistochemical markers of apoptosis and expression of pro apoptotic genes and estrogen receptor beta and decreased expression of anti apoptotic genes, androgen receptor, and estrogen receptor alpha. These data warrant clinical investigation of HE3235 for breast cancer treatment.

Additional details

Publishing Information

Journal Title
International Journal of Breast Cancer (Online)
Journal Volume
2011
Journal Issue
2011
Journal Page Range
p. 9
ISSN
2090-3189